{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:19Z","timestamp":1789609099728,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Primary cutaneous T-cell lymphomas (CTCLs) are rare lymphoproliferative malignancies characterized by significant morbidity and mortality in advanced disease stages. As curative approaches apart from allogeneic stem cell transplantation are lacking, establishing new treatment options, especially combination therapies, is crucial. Methods: This retrospective study included 11 patients with SS or MF receiving therapy with mogamulizumab in combination with ECP from four European expert centers. The response rates in the skin and blood as well as treatment use and adverse events (AE) were described. Results: 8\/11 patients (73%) showed an overall response (OR) in the skin. The mean mSWAT decreased from 98.2 \u00b1 40.8 to 34.6 \u00b1 23.8. The overall response rate (ORR) in the blood was 64% with two complete responses. During combination therapy, the mean number of S\u00e9zary cells decreased from 3365.3 \u00d7 106\/L before treatment to 1268.6 \u00d7 106\/L. The mean minimum known period without progress was 7.2 months in the skin and 7.6 months in the blood. The most common AEs were mogamulizumab-associated rash (MAR) (45.5%), anemia (27.3%), lymphocytopenia (27.8%), and infusion related reaction (16.7%). No AE led to treatment discontinuation. Conclusions: Our study presents the combination of mogamulizumab and ECP as an effective therapy in the blood and skin in CTCL with good tolerability, similar to mogamulizumab monotherapy.<\/jats:p>","DOI":"10.3390\/cancers16010141","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T07:45:32Z","timestamp":1703663132000},"page":"141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Nadia","family":"Ninosu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Melchers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany"},{"name":"Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany"},{"name":"Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kappenstein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus L\u00fcbeck, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7692-9240","authenticated-orcid":false,"given":"Nina","family":"Booken","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-7172","authenticated-orcid":false,"given":"Ma\u00ebl","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, 1007 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, 1007 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Helios Hospital Krefeld, 47805 Krefeld, Germany"},{"name":"Institute for Molecular Medicine, Medical School Hamburg, 20457 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergij","family":"Goerdt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany"},{"name":"Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany"},{"name":"Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"ref_1","first-page":"537","article-title":"S2k-Leitlinie\u2014Kutane Lymphome (ICD10 C82-C86): Update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J. Der Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","article-title":"Cutaneous T-cell Lymphoma","volume":"37","author":"Pulitzer","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39627","DOI":"10.18632\/oncotarget.17383","article-title":"Genetic rearrangements result in altered gene expression and novel fusion transcripts in S\u00e9zary syndrome","volume":"8","author":"Przybylski","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/eji.202049043","article-title":"CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver","volume":"51","author":"Nicolay","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: A multicentre, retrospective, real-world French study","volume":"37","author":"Quereux","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum\u2014Updated guidelines on the use of extracorporeal photopheresis 2020\u2014Part 1","volume":"34","author":"Knobler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0781.2012.00689.x","article-title":"Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2012","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ijd.12121","article-title":"Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: A single center clinical experience with long-term follow-up data and a brief overview of the literature","volume":"52","author":"Quaglino","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood.2022018669","article-title":"Dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma\u2014A multicenter phase II study","volume":"142","author":"Nicolay","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International Study of SS Shows Superiority of Combination Therapy & Heterogeneity of Treatment Strategies","volume":"7","author":"Campbell","year":"2023","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: Recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjd.19669","article-title":"The importance of assessing blood tumour burden in cutaneous T-cell lymphoma","volume":"185","author":"Vermeer","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/labmed\/lmy034","article-title":"Iron Deficiency Anemia in Patients Undergoing Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma","volume":"50","author":"Sanford","year":"2019","journal-title":"Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, T., Sun, J., Li, J., Zhao, Y., Zhang, T., Yang, R., and Ma, X. (2021). Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: An update evidence from 14 studies. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08363-w"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2020.10.007","article-title":"Maintenance therapy in patients with mycosis fungoides or S\u00e9zary syndrome: A neglected topic","volume":"142","author":"Stadler","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Huen, A., Haverkos, B.M., Zain, J., Radhakrishnan, R., Lechowicz, M.J., Devata, S., Korman, N.J., Pinter-Brown, L., Oki, Y., and Barde, P.J. (2020). Phase I\/Ib Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12082293"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_32","first-page":"e102","article-title":"Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and S\u00e9zary syndrome. Report of seven cases","volume":"38","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:42:45Z","timestamp":1760132565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010141"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010141","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}